lazertinib(YH25448) Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for lazertinib(YH25448) comprises 7 peer-reviewed publications across 7 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Brain Neoplasms. Most recent publication: Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial., JAMA Oncol, 2024.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.Yun J, Hong MH, Kim SY, et al. · Clin Cancer Res · 2020
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.Goss G, Tsai CM, Shepherd FA, et al. · Ann Oncol · 2019
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.Ahn MJ, Han JY, Lee KH, et al. · Lancet Oncol · 2020
- Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.Kim B, Lee J, Jang H, et al. · Adv Ther · 2022
- Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.Hong MH, Choi YJ, Ahn HK, et al. · JAMA Oncol · 2024
- Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.Han JY, Ahn MJ, Lee KH, et al. · BMC Med · 2024
- A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.Cho BC, Han JY, Kim SW, et al. · J Thorac Oncol · 2022
Publications by year
2019–2024: 7 publications.
2019
1
2020
2
2022
2
2024
2
Publications by indication
Brain Neoplasms (7)
- Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
- Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
- Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
- A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
- YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Publications by journal
- Clin Cancer Res1 paper
- Ann Oncol1 paper
- Lancet Oncol1 paper
- Adv Ther1 paper
- JAMA Oncol1 paper
- BMC Med1 paper
- J Thorac Oncol1 paper
All lazertinib(YH25448) publications (7)
2024 (2 papers)
- Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.Hong MH, Choi YJ, Ahn HK, et al. · JAMA Oncol · 2024 · Derived
- Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.Han JY, Ahn MJ, Lee KH, et al. · BMC Med · 2024 · Derived
2022 (2 papers)
- Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.Kim B, Lee J, Jang H, et al. · Adv Ther · 2022 · Derived
- A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.Cho BC, Han JY, Kim SW, et al. · J Thorac Oncol · 2022 · Derived
2020 (2 papers)
- YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.Yun J, Hong MH, Kim SY, et al. · Clin Cancer Res · 2020 · Trial result
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.Ahn MJ, Han JY, Lee KH, et al. · Lancet Oncol · 2020 · Trial result
2019 (1 paper)
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.Goss G, Tsai CM, Shepherd FA, et al. · Ann Oncol · 2019 · Trial result
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Wed, 27 May 2026 19:02:04 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).